Anna Lareida1, Robert Terziev1, Bettina Grossenbacher1, Nicolaus Andratschke2, Patrick Roth1, Sabine Rohrmann3, Rolf Stahel4, Matthias Guckenberger2, Emilie Le Rhun1,5,6,7, Michael Weller1, Fabian Wolpert8. 1. Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland. 2. Department of Radiation Oncology, University Hospital and University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. 3. Cancer Registry for the Canton of Zurich, University Hospital and University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. 4. Department of Oncology, University Hospital and University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. 5. Neuro-Oncology, Department of Neurosurgery, CHU Lille, 59000, Lille, France. 6. Neurology, Breast Cancer Department, Oscar Lambret Center, 59000, Lille, France. 7. Inserm, U-1192, University of Lille, 59000, Lille, France. 8. Department of Neurology and Brain Tumor Center, University Hospital and University of Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland. fabian.wolpert@usz.ch.
Abstract
PURPOSE: Overweight may be associated with favorable outcome whereas tumor cachexia may be associated with worse outcome in patients with metastatic cancer. Here we evaluate the association of abnormal body mass index and weight change with outcome in patients with brain metastasis. METHODS: Patients with a diagnosis of brain metastasis treated at the University Hospital Zurich (n = 703) were assessed for associations of body mass index, weight change, comorbidities and survival. RESULTS: Compared with patients with normal body mass index of 18.5-24.9 kg/m2 and a median overall survival of 9 months (95% confidence interval 7.5-10.5), overall survival was inferior in patients with body mass index < 18.5 kg/m2 (overall survival 6 months, 95% confidence interval 1.6-10.3, p = 0.04), but superior in patients with body mass index > 25 kg/m2 (overall survival 13 months, 95% confidence interval 11.0-15.0; p = 0.033). We report a median relative weight loss of 5% within the first 6 months of diagnosis of brain metastasis (95% confidence interval 3.3-6.5), and reduction exceeding the median was associated with an unfavorable outcome (weight loss < 5% 22.0 months, 95% confidence interval 19.2-24.8; weight loss > 5% 14.0 months, 95% confidence interval 11.9-16.). CONCLUSION: High body mass index is associated with better, and underweight with worse outcome in patients with brain metastasis. Conversely, weight loss above median may predict poor outcome. Future studies need to address whether vigorous treatment of tumor cachexia, e.g. by specific nutrition management, might improve outcome of patients with brain metastasis. In contrast, regimens associated with weight loss such as ketogenic diet may be detrimental.
PURPOSE: Overweight may be associated with favorable outcome whereas tumor cachexia may be associated with worse outcome in patients with metastatic cancer. Here we evaluate the association of abnormal body mass index and weight change with outcome in patients with brain metastasis. METHODS:Patients with a diagnosis of brain metastasis treated at the University Hospital Zurich (n = 703) were assessed for associations of body mass index, weight change, comorbidities and survival. RESULTS: Compared with patients with normal body mass index of 18.5-24.9 kg/m2 and a median overall survival of 9 months (95% confidence interval 7.5-10.5), overall survival was inferior in patients with body mass index < 18.5 kg/m2 (overall survival 6 months, 95% confidence interval 1.6-10.3, p = 0.04), but superior in patients with body mass index > 25 kg/m2 (overall survival 13 months, 95% confidence interval 11.0-15.0; p = 0.033). We report a median relative weight loss of 5% within the first 6 months of diagnosis of brain metastasis (95% confidence interval 3.3-6.5), and reduction exceeding the median was associated with an unfavorable outcome (weight loss < 5% 22.0 months, 95% confidence interval 19.2-24.8; weight loss > 5% 14.0 months, 95% confidence interval 11.9-16.). CONCLUSION: High body mass index is associated with better, and underweight with worse outcome in patients with brain metastasis. Conversely, weight loss above median may predict poor outcome. Future studies need to address whether vigorous treatment of tumor cachexia, e.g. by specific nutrition management, might improve outcome of patients with brain metastasis. In contrast, regimens associated with weight loss such as ketogenic diet may be detrimental.
Authors: Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-10 Impact factor: 7.038
Authors: Bette J Caan; Jeffrey A Meyerhardt; Candyce H Kroenke; Stacey Alexeeff; Jingjie Xiao; Erin Weltzien; Elizabeth Cespedes Feliciano; Adrienne L Castillo; Charles P Quesenberry; Marilyn L Kwan; Carla M Prado Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-05-15 Impact factor: 4.254
Authors: E K Masel; A S Berghoff; L M Füreder; P Heicappell; F Schlieter; G Widhalm; B Gatterbauer; U Dieckmann; P Birner; R Bartsch; S Schur; H H Watzke; C C Zielinski; M Preusser Journal: Eur J Cancer Care (Engl) Date: 2017-05-10 Impact factor: 2.520
Authors: Jill S Barnholtz-Sloan; Changhong Yu; Andrew E Sloan; Jaime Vengoechea; Meihua Wang; James J Dignam; Michael A Vogelbaum; Paul W Sperduto; Minesh P Mehta; Mitchell Machtay; Michael W Kattan Journal: Neuro Oncol Date: 2012-04-27 Impact factor: 12.300
Authors: Erin M Siegel; L Burton Nabors; Reid C Thompson; Jeffrey J Olson; James E Browning; Melissa H Madden; Gang Han; Kathleen M Egan Journal: J Neurooncol Date: 2013-05-11 Impact factor: 4.130
Authors: Daniela Meier; Andreas Lodberg; Ana Gvozdenovic; Giovanni Pellegrini; Olga Neklyudova; Walter Born; Bruno Fuchs; Marco Eijken; Sander M Botter Journal: Cancer Med Date: 2020-11-12 Impact factor: 4.452